Exploring Therapeutic Strategies in Myelodysplastic Syndromes | Supplements And Featured Publications

Shammo Previews the Potential of Pevonedistat Combo in High-Risk MDS

July 23, 2020

Jamile M. Shammo, MD, discusses the current treatment landscape of high-risk MDS recent data with the investigational small molecule inhibitor of the NEDD8-activating enzyme pevonedistat, and ongoing research efforts in the space.

x